Tag Archive for: Seagen

The company stated that Adcetris, extended survival in patients with the most common type of lymphoma in a late-stage study, bolstering efforts to expand the use of the treatment gained through its $43 billion purchase of Seagen.

In its final decision, the U.S. PTO invalidated all of the claims in Seagen’s patent 10,808,039, which covers the use of auristatin peptides connected to antibody-drug conjugates (ADCs) via a specific linker technology.

Amid falling COVID-19 revenues, Pfizer continues to invest in antibody-drug conjugates in a deal with Nona Biosciences worth $1 billion as its $43 billion Seagen buy closed on Thursday.

Pfizer has agreed to donate the rights of royalties from sales of cancer drug Bavencio to address concerns from U.S. antitrust regulators related to its $43-billion deal to buy Seagen.

The European Commission said the deal would not significantly reduce competition in the 27-country European Union nor would it have a negative impact on prices.

Pfizer’s mRNA vaccine, Comirnaty, was the company’s highest-selling product once again, but leaders are looking to the Seagen acquisition for future growth.

The companies have started a collaboration worth up to $3.4 billion to develop a portfolio of degrader-antibody conjugates, a potentially new class of antibodies that selectively kill cancer cells.

Interim data from the Phase III innovaTV 301 trial showed that Genmab and Seagen’s antibody-drug conjugate Tivdak (tisotumab vedotin-tftv) met its primary endpoint, leading to significant survival benefit in patients with metastatic cervical cancer, the companies announced Monday.

Today the company announced that its breast cancer therapy in combination with Roche’s Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.

Regulators have recently increased scrutiny on high-value deals.